ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Suptavumab Does Not Meet Primary Endpoint
August 15, 2017Regeneron Pharmaceuticals announced a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of preventing medically-attended RSV infections in infants. -
Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with
March 06, 2017Sanofi and its vaccines global business unit Sanofi Pasteur announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, -
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Mon
February 28, 2017Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases, -
Updated Phase I Data show Bavarian Nordic's vaccine candidate induces broad and durable immune respo
February 27, 2017Antibody levels maintained against multiple targets 6 months post vaccination.
Pharma Sources Insight January 2025
